

# Intestinal archaea inversely associated with childhood asthma

Citation for published version (APA):

Barnett, D., Mommers, M., Penders, J., Arts, I., & Thijs, C. (2019). Intestinal archaea inversely associated with childhood asthma. *Journal of Allergy and Clinical Immunology*, 143(6), 2305-2307. <https://doi.org/10.1016/j.jaci.2019.02.009>

## Document status and date:

Published: 01/06/2019

## DOI:

[10.1016/j.jaci.2019.02.009](https://doi.org/10.1016/j.jaci.2019.02.009)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

although to a greatly reduced extent compared with WT B<sub>mem</sub> cells (see Fig E6, A-C, in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). Consistent with this, the few B<sub>mem</sub> cells present in STK4-deficient patients were capable of differentiating into ASCs *in vitro*, although at reduced levels (see Fig E6, D). Interestingly, despite the impaired specific antibody secretion in mice with *Stk4*<sup>Y88del/Y88del</sup> B cells, STK4 deficiency did not quantitatively affect the ability of these SW<sub>HEL</sub> B cells to generate plasma cells *in vivo* (Fig 2, I-K). Thus, similar to B cells from STK4-deficient patients, *Stk4*<sup>Y88del/Y88del</sup> B cells are able to differentiate into plasma cells, but these plasma cells do not secrete adequate amounts of specific antibody.

STK4 is a multifunctional kinase that phosphorylates multiple cellular proteins, including those in the Hippo signaling pathway.<sup>E8,E9</sup> Many of these substrates are also phosphorylated by its paralog, STK3, suggesting STK3 might functionally compensate for STK4 deficiency. Indeed, B-cell defects are more readily observed in *Stk3/Stk4* double-knockout mice.<sup>E5</sup> Interestingly, STK4 has been shown to phosphorylate FOXO1 and promote its nuclear localization,<sup>E10</sup> and FOXO1 was recently shown to be required for dark zone formation and GC maintenance.<sup>E11-E13</sup> However, although FOXO1 levels were decreased in *Stk4*<sup>Y88del/Y88del</sup> and *Stk4*<sup>-/-</sup> GC B cells, we could not rescue the GC defect through retroviral overexpression of *Foxo1* (see Fig E7 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)), suggesting that other mechanisms might also be involved.

Another limitation of our study is the small number of patients involved, which prevents any firm conclusion, especially regarding differences in serum immunoglobulin levels in our cohort of 9 patients and the previously reported 14 patients. Nevertheless, our data establish a B cell–intrinsic requirement for STK4 in humoral immunity in mice and human subjects.

We thank David Langley for help with the STK4 crystal structure. We gratefully acknowledge the patients and families involved in the study.

Imogen Moran, PhD<sup>a,b</sup>  
Danielle T. Avery, BSc<sup>a</sup>  
Kathryn Payne, BSc<sup>a</sup>  
Helen Lenthall, MMSc<sup>a</sup>  
E. Graham Davies, MD<sup>c</sup>  
Siobhan Burns, MD, PhD<sup>d,e</sup>  
Winnie Ip, MD<sup>c</sup>  
Matijfjedas M. Oleastro, MD<sup>f</sup>  
Ismail Reisli, MD<sup>g</sup>  
Sukru Guner, MD<sup>g</sup>  
Sevgi Keles, MD<sup>g</sup>  
Luigi Notarangelo, MD<sup>h</sup>  
Elissa K. Deenick, PhD<sup>a,b</sup>  
Christopher C. Goodnow, PhD<sup>a,b</sup>  
David Zahra, PhD<sup>a</sup>  
Robert Brink, PhD<sup>a,b</sup> CIRCA<sup>i</sup>  
Melanie Wong, PhD<sup>j,k</sup>  
Stuart G. Tangye, PhD<sup>a,b</sup>  
Cindy S. Ma, PhD<sup>a,b</sup>  
Tri Giang Phan, PhD<sup>a,b</sup>

From <sup>a</sup>the Immunology Division, Garvan Institute of Medical Research, Sydney, Australia; <sup>b</sup>St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia; <sup>c</sup>Infection, Immunity and Inflammation Theme, UCL Great Ormond Street Institute of Child Health, and the Department of Immunology, Great Ormond Street Hospital, London, United Kingdom; <sup>d</sup>the Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom; <sup>e</sup>the Institute of Immunology and Transplantation, University College London, London, United Kingdom; <sup>f</sup>the Immunology and Rheumatology Department, Hospital de Pediatría "Dr Juan P. Garrahan," Buenos Aires, Argentina; <sup>g</sup>the Division of Pediatric Immunology and

Allergy, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey; <sup>h</sup>the Laboratory of Clinical Immunology and Microbiology, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md; <sup>i</sup>Clinical Immunogenomics Research Consortium Australia, Darlinghurst, Australia; <sup>j</sup>Children's Hospital at Westmead, Westmead, Australia; <sup>k</sup>the Faculty of Medicine, University of Sydney, Sydney, Australia. E-mail: [t.phan@garvan.org.au](mailto:t.phan@garvan.org.au).

\*These authors contributed equally to this work as senior authors.

Supported by National Health and Medical Research Council (NHMRC) grant ID1139865, the Office of Health and Medical Research of the NSW State Government, the John Cook Brown Foundation, and the Jeffrey Modell Foundation. The contents of this article are solely the responsibility of the authors and do not reflect the views of the NHMRC.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

## REFERENCES

1. Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schäffer AA, et al. The phenotype of human STK4 deficiency. *Blood* 2012;119:3450-7.
2. Nehme NT, Schmid JP, Debeurme F, André-Schmutz I, Lim A, Nitschke P, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. *Blood* 2012;119:3458-68.
3. Halacsi SO, Ayvaz DC, Sun-Tan C, Erman B, Uz E, Yilmaz DY, et al. STK4 (MST1) deficiency in two siblings with autoimmune cytopenias: a novel mutation. *Clin Immunol* 2015;161:316-23.
4. Crequer A, Picard C, Patin E, D'Amico A, Abhyankar A, Munzer M, et al. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. *PLoS One* 2012;7:e44010.
5. Dang TS, Willet JDP, Griffin HR, Morgan NV, O'Boyle G, Arkwright PD, et al. Defective leukocyte adhesion and chemotaxis contributes to combined immunodeficiency in humans with autosomal recessive MST1 deficiency. *J Clin Immunol* 2016;36:117-22.
6. Schipp C, Fischer U, Schlütermann D, Hönscheid A, Nabhani S, Höll J, et al. EBV negative lymphoma and autoimmune lymphoproliferative syndrome like phenotype extend the clinical spectrum of primary immunodeficiency caused by STK4 deficiency. *Front Immunol* 2018;9:2400.
7. Kurz AR, Puenster M, Rohwedder I, Ramadass M, Schafer K, Harrison U, et al. MST1-dependent vesicle trafficking regulates neutrophil transmigration through the vascular basement membrane. *J Clin Invest* 2016;126:4125-39.
8. Li C, Bi Y, Li Y, Yang H, Yu Q, Wang J, et al. Dendritic cell MST1 inhibits Th17 differentiation. *Nat Commun* 2017;8:14275.
9. Katagiri K, Katakai T, Ebisuno Y, Ueda Y, Okada T, Kinashi T. Mst1 controls lymphocyte trafficking and interstitial motility within lymph nodes. *EMBO J* 2009;28:1319-31.

Available online February 20, 2019.  
<http://dx.doi.org/10.1016/j.jaci.2019.02.010>

## Intestinal archaea inversely associated with childhood asthma



### To the Editor:

Both laboratory and epidemiologic studies have demonstrated the importance of the gut microbiota in immunologic development, childhood asthma, and allergic disease pathophysiology.<sup>1</sup> Although most studies have focused on bacteria, the methanogenic archaea that live alongside them are relatively understudied. Archaea are prokaryotic microorganisms belonging to their own domain of life distinct from bacteria and Eukaryota.

*Methanobrevibacter smithii* and *Methanosphaera stadtmanae* are the most abundant archaeal species in the gut.<sup>2</sup> Bang et al<sup>3</sup> and Blais-Lecours et al<sup>4</sup> demonstrated that *M stadtmanae* is particularly immunogenic in human cells and mice. Accordingly, we hypothesized that archaea, like bacteria, might play a role in childhood asthma or allergic disease risk, and in this letter we present the first epidemiologic evidence linking an archaeal species, *M stadtmanae*, with lower asthma risk.

We conducted cross-sectional analyses using fecal samples available at 6 to 10 years of age for a subset of children participating in the KOALA birth cohort study in The

**TABLE I.** Results for the presence of archaea (yes/no)

Exposure	Outcome	Sample size	OR (95% CI), crude*	OR (95% CI), adjusted*
<i>M. stadtmanae</i>	Asthma	472	0.38 (0.10-1.10)	<b>0.32 (0.08-0.98)</b>
	Eczema	472	0.72 (0.34-1.46)	0.68 (0.30-1.42)
	Aeroallergen sensitized	355	1.04 (0.45-2.30)	0.83 (0.32-2.02)
	Food allergen sensitized	354	0.82 (0.27-2.09)	0.69 (0.21-1.95)
<i>M. smithii</i>	Asthma	472	1.17 (0.63-2.27)	1.09 (0.56-2.20)
	Eczema	472	1.38 (0.86-2.25)	1.32 (0.81-2.18)
	Aeroallergen sensitized	355	0.96 (0.57-1.63)	1.05 (0.59-1.89)
	Food allergen sensitized	354	1.03 (0.56-1.94)	1.30 (0.68-2.59)

Boldface text indicates which results reached statistical significance,  $P < .05$ .

\*The crude model is adjusted only for study design–related variables: fecal sampling round and recruitment group. The fully adjusted model also included birth mode and place, antibiotic exposure, farm animal exposure, cat/dog exposure, body mass index  $z$  score, maternal age at delivery, maternal education, parental atopy, sibling atopy, sex, organic dairy consumption, and abundance of the other archaeal species.

**TABLE II.** *M. stadtmanae* abundance and asthma risk (sample size = 472)

<i>M. stadtmanae</i> abundance	No.	Asthma prevalence (%)	OR (95% CI), crude	OR (95% CI), adjusted
Absent	433	17.3	1.00 (reference)	1.00 (reference)
Low abundance	23	13.0	0.37 (0.08-1.35)	0.43 (0.08-1.73)
High abundance	16	6.2	0.40 (0.02-2.03)	0.20 (0.01-1.18)
<i>P</i> value for linear association with interval-scale abundance categories			.096	<b>.036</b>

Boldface text indicates which results reached statistical significance,  $P < .05$ .

Netherlands, as shown in Fig E1 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org). The KOALA study, which is described in detail elsewhere,<sup>5</sup> consists primarily of children ( $n = 2359$ ) whose mothers were recruited as healthy pregnant women from an ongoing prospective cohort study on pregnancy-related pelvic girdle pain. Additionally, an "alternative recruitment group" of 496 women was recruited through advertisements in organic food shops, anthroposophic doctors and midwives, Steiner schools, and dedicated magazines. The KOALA study was approved by the Medical Ethical Committee of the Maastricht University/University Hospital of Maastricht and the National Ethical Committee for Medical Research. All parents signed informed consent forms.

We requested childhood fecal samples from 1432 families, targeting those who had already provided other biosamples, such as maternal and child blood samples. We also oversampled for 27 asthmatic patients from within the KOALA cohort to increase statistical power. We received 672 samples and excluded samples with transport times of greater than 4 days, leaving 472 available for analysis. We quantified *M. smithii* and *M. stadtmanae* in these samples by using quantitative PCR and targeting regions of the 16S rRNA genes specific for these species.<sup>5</sup>

All 472 children had data on asthma and eczema diagnoses, symptoms, and medication use from up to 4 parentally completed questionnaires spanning 6 to 10 years of age. Three hundred fifty-five children had total and specific serum IgE measurements (with 1 missing for food allergens), and 337 had spirometric lung function data. These blood samples and spirometric readings were taken during home visits at 6 to 10 years of age by trained research nurses. Serum specific IgE levels defined aeroallergen and food allergen sensitization outcomes, and the normalized FEV<sub>1</sub>/forced vital capacity ratio was used as a continuous lung function outcome. Asthma diagnoses were based on modified International Study of Asthma and Allergies in Childhood questionnaires requiring a reported physician's diagnosis, as well as reported

recent symptoms or medication use. Further details of data collection protocols and outcome definitions are included in the Methods section in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org).

Asthma and eczema are overrepresented in the study population relative to the whole KOALA cohort, as was expected from the oversampling of asthmatic children (16.7% vs 10.4% and 34.1% vs 28.5%, see Table E1 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). A larger proportion of the study population (24.8%) are from the alternative recruitment group than in the overall KOALA cohort (17.4%). This was also expected because the alternative recruits are more likely than the conventional recruits to have early-life biosamples, such as infant blood, because KOALA's alternative recruitment program began at approximately the same time as the biosampling program. Early-life biosample availability was a criterion for inclusion in the childhood fecal sampling program.

Further description of the study population can be found in Table E3 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org).

*M. stadtmanae* and *M. smithii* were detectable in 8.3% and 78.2% of samples, respectively.<sup>6</sup> Because abundance distributions of both *M. stadtmanae* and *M. smithii* followed an apparent trimodal pattern (see Fig E2 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)), we also classified participants into 3 abundance categories.

We tested for associations between the presence of each archaeal species and the risk of our primary outcome of asthma using logistic regression models adjusted for multiple potential confounders (Table I). We adjusted for recruitment group and fecal sampling round in all analyses. No significant interaction between recruitment group and archaeal exposure was found, and therefore pooling these groups was considered appropriate. Analyses involving serum IgE data were also adjusted for analytic batch numbers.

The vast majority of participants had no missing covariate data. Seven covariates had 5 or fewer missing data, which we imputed with the most common category or mean value. Organic dairy consumption was imputed for 19 children by using the categories predicted by using a regression model based on prior dietary and lifestyle information.

Our results indicate that the presence of *M. stadtmanae* is associated with a lower risk of asthma at 6 to 10 years of age (adjusted odds ratio [OR], 0.32; 95% CI, 0.08–0.98;  $P = .045$ ; Table I). Furthermore, the risk of asthma showed a monotonic decrease over the 3 categories of *M. stadtmanae* abundance (adjusted  $P = .036$  for linear trend over the *M. stadtmanae* abundance categories, Table II). No significant interaction was found between *M. stadtmanae* exposure and parental asthma history ( $P = .495$ ), suggesting that the association does not significantly differ by parental asthma status.

For secondary outcomes, *M. stadtmanae* also appeared to be associated with a slightly lower likelihood of eczema, aeroallergen sensitization, and food allergen sensitization, but these associations did not reach statistical significance (Table I). *M. stadtmanae* was not associated with either of the continuous outcomes of total serum IgE or FEV<sub>1</sub>/forced vital capacity  $z$  score (see Table E4 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). We found no significant associations between *M. smithii* and any outcome (Tables I and see Table E4). We also conducted a complete case analysis that produced similar results (see Table E5 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)).

Additionally, to check whether the oversampling of asthma cases in the second sampling round had introduced any bias, we repeated the analyses with only the 372 children sampled in the first round (see Table E6 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). Similar ORs were observed in this subgroup (eg, *M. stadtmanae* presence and asthma: OR, 0.39; 95% CI, 0.06–1.60). The lower precision observed was expected from the smaller sample size and fewer asthma cases, and this sensitivity analysis otherwise showed no evidence of any bias introduced by the oversampling.

Because of the low prevalence of *M. stadtmanae* and cross-sectional study design, our results should be interpreted with caution. Although bacterial species not examined in our analysis might confound this association, we speculate that a mechanistic link between *M. stadtmanae* and allergic disease appears plausible. Prior evidence demonstrates the airway and gut immunogenicity of *M. stadtmanae* in mouse models and human cells.<sup>3,7</sup> Epidemiologic evidence also indicates a timing-dependent relationship between asthma risk and exposure to farm environments<sup>8</sup> where *M. stadtmanae* is present.<sup>9</sup> However, farm exposure has also been associated with risk of atopy, which our study does not show.

Exposure to immunogenic bacterial species in infancy has been shown to be tolerogenic and reduce asthma risk.<sup>1</sup> Our study identifies an association between the presence of *M. stadtmanae* at school age and lower asthma risk, leading us to speculate that early-life archaeal exposures might also be tolerogenic. Therefore we encourage further research into the immunologic roles of archaea.

We would like to thank Christel Driessen and Erik Beuken for their technical assistance with quantitative PCR analyses.

David J. M. Barnett, MA<sup>a</sup>  
Monique Mommers, PhD<sup>b</sup>  
John Penders, PhD<sup>c</sup>  
Ilja C. W. Arts, PhD<sup>d</sup>  
Carel Thijs, MD, PhD<sup>b</sup>

From <sup>a</sup>the Department of Epidemiology, Maastricht University, Maastricht, The Netherlands; <sup>b</sup>the Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands; <sup>c</sup>the Department of Medical Microbiology, School of Nutrition and Translational Research in Metabolism (NUTRIM), Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre, Maastricht, The Netherlands; and <sup>d</sup>the Department of Epidemiology, Maastricht Centre for Systems Biology (MaCSBio), CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands. E-mail: [david.barnett@maastrichtuniversity.nl](mailto:david.barnett@maastrichtuniversity.nl).

The microbiological analysis was partly supported by TI Food and Nutrition. Funding for data collection was received from the Netherlands Organisation for Health Research and Development (grant 2100.0090), the Netherlands-America Foundation (grants 3.2.03.48, 3.2.07.022), Stichting Astma Bestrijding, Netherlands Heart Foundation (grant 2008B112), Royal Friesland Foods (currently FrieslandCampina), the Netherlands Sugar Foundation, and the Netherlands Ministry of Economic Affairs.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

## REFERENCES

1. Stokholm J, Blaser MJ, Thorsen J, Rasmussen MA, Waage J, Vinding RK, et al. Maturation of the gut microbiome and risk of asthma in childhood. *Nat Commun* 2018;9:141.
2. Lurie-Weinberger MN, Gophna U. Archaea in and on the human body: health implications and future directions. *PLoS Pathog* 2015;11:e1004833.
3. Bang C, Weidenbach K, Gutschmann T, Heine H, Schmitz RA. The intestinal archaea *Methanospaera stadtmanae* and *Methanobrevibacter smithii* activate human dendritic cells. *PLoS One* 2014;9:e99411.
4. Blais Lecours P, Duchaine C, Taillefer M, Tremblay C, Veillette M, Cormier Y, et al. Immunogenic properties of archaeal species found in bioaerosols. *PLoS One* 2011;6:e23326.
5. Kummeling I, Thijs C, Penders J, Snijders BEP, Stelma F, Reimerink J, et al. Etiology of atopy in infancy: the KOALA birth cohort study. *Pediatr Allergy Immunol* 2005;16:679–84.
6. Mbakwa CA, Penders J, Savelkoul PH, Thijs C, Dagnelie PC, Mommers M, et al. Gut colonization with *Methanobrevibacter smithii* is associated with childhood weight development. *Obesity (Silver Spring)* 2015;23:2508–16.
7. Bernatchez E, Gold MJ, Langlois A, Blais-Lecours P, Boucher M, Duchaine C, et al. *Methanospaera stadtmanae* induces a type IV hypersensitivity response in a mouse model of airway inflammation. *Physiol Rep* 2017;5:e13163.
8. Poole JA. Farming-associated environmental exposures and effect on atopic diseases. *Ann Allergy Asthma Immunol* 2012;109:93–8.
9. Nehmé B, Gilbert Y, Létourneau V, Forster RJ, Veillette M, Villemur R, et al. Culture-independent characterization of archaeal biodiversity in swine confinement building bioaerosols. *Appl Environ Microbiol* 2009;75:5445–50.

Available online February 20, 2019.  
<http://dx.doi.org/10.1016/j.jaci.2019.02.009>

## Prophylactic allergen immunotherapy with Der p 2 prevents murine asthma by regulating lung GM-CSF



### To the Editor:

The prevalence of allergic diseases is increasing, urging new ways of prevention. Allergen immunotherapy (AIT) is currently the only clinical intervention that can alter the natural course of allergy and can offer long-term clinical benefit. Although AIT is traditionally used as a treatment in patients with established disease, the National Institutes of Health's Immune Tolerance Network has proposed that prophylactic AIT could also be used as a primary prevention for new sensitizations and allergic disease in high-risk children born to atopic parents and with a personal